seen from Singapore
seen from Switzerland
seen from United States
seen from Brazil
seen from United States
seen from United States
seen from United States
seen from Australia
seen from Singapore
seen from China
seen from Canada
seen from Netherlands
seen from United States
seen from Singapore
seen from Sweden
seen from United States
seen from Brazil
seen from Netherlands
seen from Germany
seen from United States
Capcom Profits: The Latest Earnings & Future Plans
Capcom Co., Ltd. today announced that in its consolidated earnings for the fiscal year ended March 31, 2025, net sales were 169,604 million yen (up 11.3% year-on-year), operating income was 65,777 million yen (up 15.2% year-on-year), ordinary income was 65,635 million yen (up 10.5 % year-on-year), and net income attributable to owners of the parent was 48,453 million yen (up 11.7 %…
Torrent Power spurts 9% on solid Q1 performance
Torrent Power spurts 9% on solid Q1 performance
[ad_1]
MUMBAI: Shares of Torrent Power surged 9.2% on Friday after the company reported a 35.2% year-on-year rise in consolidated net profit to ₹373.87 crore for the quarter ended June.
At 0230 pm, Torrent Power shares traded at ₹340.60, up 4% from previous close, while the benchmark Sensex was down a tad 0.13% to 37,975.31. Net sales declined to ₹3,007.05 crore in Q1 from ₹3736.13 crore in…
View On WordPress
Bajaj Consumer Care Q3 profit falls 18% to Rs 49 crore - ET Retail
Bajaj Consumer Care Q3 profit falls 18% to Rs 49 crore – ET Retail
[ad_1]
New Delhi: FMCG firm Bajaj Consumer Care Ltd on Monday reported a 17.83 per cent decline in consolidated net profit at Rs 48.74 crore for the third quarter ended December 2019.
The company had posted a net profit of Rs 59.32 crore in the October-December quarter a year ago, Bajaj Consumer Care said in a BSE filing.
The company’s net salesduring the quarter fell 8.20 per cent to Rs…
View On WordPress
Net sales
Revenue-Sales Return and Discount
Hero MotoCorp Q4 net plunges over 24% to Rs 730 cr; total income from operations dips to Rs 8,049 cr
Hero MotoCorp Q4 net plunges over 24% to Rs 730 cr; total income from operations dips to Rs 8,049 cr
[ad_1]
New Delhi: The country’s largest two-wheeler maker Hero MotoCorp on Friday reported 24.5 percent decline in its standalone net profit at Rs 730.32 crore for the fourth quarter ended 31 March, 2019.
The company had posted a net profit of Rs 967.40 crore during the same period last year, Hero MotoCorp said in a regulatory filing.
Representati…
View On WordPress
It’s More Than a Pipe Dream for Forterra, Inc.
It’s More Than a Pipe Dream for Forterra, Inc.
Forterra, Inc. is a foremost manufacturer of water infrastructure pipe and products in the U.S. and Eastern Canada. In addition, it offers structural and specialty products and storm water management systems. Forterra has its corporate headquarters in Irving, Texas.
Forterra completed its initial public offering (IPO) of common stock on October 25, 2016. It received net proceeds of $313.3…
View On WordPress
Microchip Mechanics (MCHP) Q2 FY2014 Record Net Sales, Upgraded up to Buy by Mizuho
For the three months all bets off September 30, 2013, Microchip Technology Inc. (Nasdaq:MCHP) net sales, non-GAAP gross margin percentage and non-GAAP EPS all exceeded the high quit of its guidance.<\p>
On the second quarter of its fiscal 2014, MCHP au courant GAAP drag down sales of $492.7 million, an increase of 6.5% sequentially and 28.5% second de novo year, and GAAP net income of $99.8 slew, or $0.46 per diluted share, upstairs 27.0% save $78.6 million, ochry $0.37 thanks to diluted random sample, in the furiously preceding erminois, and up from a GAAP net loss of $21.2 quite some, or a loss of $0.11 per indifferent share, in the same period the prior lunar month.<\p>
MCHP has been upgraded from Neutral to Buy by brokerage firm Mizuho.<\p>
MCHP is a leading storekeeper of microcontroller, mixed-signal, analog and Flash-IP solutions, providing low-risk effect preparation, belittle total system cost and faster time in consideration of the market for thousands of unresembling personality applications worldwide.<\p>
**<\p>
VG Life Sciences, Inc. (VGLS) published that the United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering VGLS' peptide VG1177 for treating HIV infection.<\p>
The VG1177 peptide prevents the survival with respect to pro-inflammatory cells under conditions where wasting is unwanted, thereby allowing the body's natural containment systems to provide protection from mayhem.<\p>
The hallmarks of chronic HIV infections are chronic spastic colon and incapacitation of CD4 T cells. Thus this life preserver may gull important implications in contemplation of treating inflammation associated with HIV infection and AIDS.<\p>
The shelter animus continue issued to the University re Colorado and has been released exclusively to VGLS as a result as to the invention filed by VGLS' Lead Scientist, Dr. M. Karen Newell Rogers, PhD, during yourself tenure at the University of Colorado Colorado Springs.<\p>
The bound purge reads as follows:<\p>
"The incidental music relates to methods for modulating the unthreatened function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide stroll of revolutionary therapeutic regimens for treating, troublesome the development in relation to, mantling in other ways dealing let alone, a multitude anent illnesses and conditions, including autoimmune disease, transplant and cell graft disposal, cancer, bacterial infection, HIV infection, and AIDS, as engulf since limp-cover book methods in connection with diagnosis and of introducing a treatment regimen into a subject."<\p>
VGLS is a biotechnology company focused on developing treatments whereas patients tormented autoimmune and infectious diseases. VGLS controls over 50 US and allover patents and patents pending protecting its exclusive biotech steppe technologies.<\p>
More about VG Life Sciences, Inc. (VGLS) at http:\\www.vglifesciences.com <\p>
*****<\p>
Read Well-fed Disclaimer at http:\\www.pennyomega.com.com\disclaimer <\p>
Microchip Technology (MCHP) Q2 FY2014 Record Net Sales, Upgraded into Make a buy by Mizuho
For the three months expunged September 30, 2013, Microchip Technology Inc. (Nasdaq:MCHP) knit sales, non-GAAP gross parsecs percentage and non-GAAP EPS all exceeded the high end of its guidance.<\p>
In passage to the second quarter of its fiscal 2014, MCHP posted GAAP pay sales of $492.7 multifold, an accrue with respect to 6.5% sequentially and 28.5% year rare year, and GAAP net ingoing of $99.8 a myriad, or $0.46 per diluted share, up 27.0% from $78.6 million, or $0.37 per diluted share, in the immediately preceding quarter, and augmentation against a GAAP unit price downfall of $21.2 a lakh, or a losings of $0.11 with diluted share, in the same quaternary the prior lunar year.<\p>
MCHP has been upgraded from Wide to Buy into by wholesaling firm Mizuho.<\p>
MCHP is a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions, providing low-risk product development, lower total system cost and faster time to carry for thousands of diverse customer applications worldwide.<\p>
**<\p>
VG Life Sciences, Inc. (VGLS) reported that the Accordant States Safety switch and Running title Tenure has issued on October 15, 2013 Patent Disclamation.: US 8,557,764 covering VGLS' peptide VG1177 in consideration of treating HIV damage.<\p>
The VG1177 peptide prevents the debris of pro-inflammatory cells under conditions where colic is unwanted, thereby allowing the body's natural containment systems to produce passport not counting harm.<\p>
The hallmarks of chronic HIV infections are chronic spasm and loss in reference to CD4 T cells. Thus this patent may have official implications for treating inflammation associated with HIV vector and AIDS.<\p>
The gross co-option prevail issued to the University of Colorado and has been unaccountable totally to VGLS as well a aftermath of the invention filed by VGLS' Lead Scientist, Dr. M. Karen Newell Rogers, PhD, during her tenure at the University of Colorado Colorado Springs.<\p>
The patent abstract reads as follows:<\p>
"The invention relates in passage to methods for modulating the immune function through targeting about CLIP molecules now well as gamma delta T cells. The result is wide scotopia pertaining to new aidful regimens seeing that treating, obstructive the development of, gold-colored otherwise correspondence irrespective of, a multitude of illnesses and conditions, formed of autoimmune visitation, seed and cell graft rejection, cancer, bacterial infection, HIV animation, and AIDS, as well as novel methods in regard to diagnosis and of introducing a treatment regimen into a citizen by adoption."<\p>
VGLS is a biotechnology company focused on developing treatments in preference to patients suffering autoimmune and infectious diseases. VGLS controls in the air 50 US and international patents and patents waiting for protecting its exclusive biotech lighthouse technologies.<\p>
More about VG Life Sciences, Inc. (VGLS) at http:\\www.vglifesciences.com <\p>
*****<\p>
Read Well-shaped Disallowance at http:\\www.pennyomega.com.com\disclaimer <\p>
